Press Release

"Operational" growth reflects percentage change over the prior year excluding the impact of exchange rates.

"Operational" growth reflects percentage change over the prior year excluding the impact of exchange rates.

2011 Net Earnings Excluding Specified Items excludes after-tax charges of $1.4 billion, or $0.92 per share, related to litigation reserves (see Footnote 3 above), $75 million, or $0.05 per share, associated with the acquisition of Solvay Pharmaceuticals and $78 million, or $0.05 per share, for previously announced cost reduction initiatives and other. These items were partially offset by a favorable adjustment to tax expense of $51 million, or $0.03 per share, as a result of the resolution of various prior years' international and U.S. tax positions.

2010 Net Earnings Excluding Specified Items excludes after-tax charges of $513 million, or $0.33 per share, associated primarily with the acquisition of Solvay Pharmaceuticals, including restructuring plans, as well as cost reduction initiatives, $70 million, or $0.05 per share, for costs of a nutritional product recall and the withdrawal of sibutramine, and $158 million, or $0.10 per share, for impairment of the intangible asset related to sibutramine.

Q1) 

A1) 

Beginning this year, we have characterized Abbott's major businesses into three categories, based on their underlying attributes. These include:

• Proprietary Pharmaceuticals, including our U.S. and international proprietary pharmaceutical products. We globalized this business, creating one global division to allow for streamlined commercial efforts and coordination between functions.

• Durable Growth Businesses, including Nutritionals, Established Pharmaceuticals, Core Laboratory Diagnostics, Diabetes Care and Point of Care Diagnostics. These businesses are less dependent on significant R&D investment, have minimal patent risk, and operate in generally stable markets, with many products paid for directly by the consumer.

• Innovation-Driven Device Businesses, including Vascular, Medical Optics and Molecular Diagnostics. These businesses have a relatively lower patent risk, and require a moderate level of R&D spend, resulting in new products that generate more significant revenue and profit contribution.

Proprietary Pharmaceuticals sales increased 13.5 percent, including 4.6 percent from favorable foreign exchange, driven by strong growth across a number of key franchises in the United States and internationally. HUMIRA® was a significant contributor to growth in the quarter with U.S. sales growth of 18.1 percent and International sales growth of 32.0 percent, including 13.4 percent favorable foreign exchange. Double-digit sales growth for Lupron® and Synthroid® also contributed to the quarter.

Durable Growth Business sales increased 15.3 percent, including 6.2 percent favorable foreign exchange, driven by Established Pharmaceuticals and Nutritionals, as well as steady sales growth in our Core Laboratory Diagnostics, Diabetes Care and Point of Care Diagnostics businesses. Established Pharmaceuticals sales, which include sales of our branded generics pharmaceuticals outside of the United States, increased 22.6 percent. Worldwide Nutritional products sales growth was 12.6 percent, with 15.7 percent growth in International Nutritionals.

Innovation-Driven Devices sales increased 6.0 percent, including 5.2 percent favorable foreign exchange, driven by 17.2 percent growth in Molecular Diagnostics, 15.8 percent growth in International Vascular and 6.0 percent growth in Medical Optics.

Q2) 

What were emerging markets sales?

A2) 

Abbott total-company emerging-markets sales were $ 2.6 billion, up 21.0 percent in the quarter, reflecting strong growth across all divisions. In our Established Pharmaceuticals business, we saw strong performance in Russia, India and China. In Nutritionals, we saw particularly strong growth in Asia and Latin America, where we are expanding our presence and gaining share with the introduction of new products.

In our Diagnostics business, we continue to perform well in China, where we are placing new ARCHITECT® systems and continuing to penetrate the market. And, in our Vascular business, we saw strong growth across all key emerging markets, driven by double-digit procedure volumes in many of these markets, as well as Abbott market share gains.

Q3) 

What was the gross margin ratio in the quarter?

A3) 

The gross margin ratio before and after specified items is shown below (dollars in millions):

The adjusted gross margin ratio of 60.4 percent in the third quarter was above our previous outlook for the quarter, driven by favorable product mix.

Q4) 

What drove SG&A and R&D investment?

A4) 

Both ongoing SG&A and R&D investment reflect Abbott's continued investment in programs to drive future growth. Ongoing R&D expense as a percentage of sales was 10.1 percent, reflecting continued investment in Abbott's broad-based pipeline, including programs in vascular devices, immunology, neuroscience, oncology and HCV.

Q5) 

What was the tax rate?

A5) 

The ongoing tax rate this quarter was 15.2 percent, in line with Abbott's previous forecast.

Q6) 

How did specified items affect reported results?

A6) 

Specified items impacted third-quarter results as follows:

Litigation reserves relate to ongoing settlement discussions in the previously disclosed investigation by the U.S. Department of Justice, through the U.S. Attorney for the Western District of Virginia, related to Depakote. The discussions are ongoing, and until concluded, there can be no certainty about definitive resolution. Restructuring/integration (acquisitions and other/cost reductions) is primarily associated with restructuring and integration costs for the Solvay Pharmaceuticals acquisition. This item also includes previously announced cost reduction initiatives to improve efficiencies in the pharmaceutical, vascular, and core laboratory diagnostics businesses.

2011 Taxes on earnings includes a favorable adjustment to tax expense of $51 million, or $0.03 per share, as a result of the resolution of various prior years' international and U.S. tax positions. The impact of the remaining specified items by Consolidated Statement of Earnings line item is as follows (dollars in millions):

Q7) 

What are the key areas of focus in Abbott's broad-based pipeline?

A7) 

We continue to advance our broad-based pipeline. In 2011, we have launched several new products or indications, including variations of Lupron Depot, Androgel® 1.62 percent, Creon® infant-specific dosage, XIENCE nano™, TREK® Coronary Balloon System, the RX Herculink Elite Renal Stent System, our ALK gene molecular diagnostics test and the FreeStyle® InsuLinx Blood Glucose Monitoring System. We advanced elotuzumab and bardoxolone into Phase 3 development and submitted XIENCE PRIME™ and HUMIRA ulcerative colitis (UC) for regulatory review. Following are highlights from breakthrough research across our pharmaceuticals, medical products and nutritionals pipelines:

• Hepatitis C

• Abbott's antiviral program is focused on developing treatments for hepatitis C (HCV), a disease that affects more than 180 million people worldwide, with approximately 3 to 4 million people newly infected each year. Abbott's broad-based HCV programs include its partnership with Enanta Pharmaceuticals to discover protease inhibitors, as well as its internal programs focused on additional viral targets.
• Abbott currently has three mechanisms of action in Phase 2 clinical trials, including protease, polymerase and NS5A inhibitors. Abbott is evaluating combinations of these compounds, both with and without the current standard of care, a strategy that has the potential to markedly transform current treatment practices by shortening therapy duration, improving tolerability and increasing cure rates.

• Chronic Kidney Disease

• Bardoxolone, an investigational treatment for chronic kidney disease (CKD), is a first-in-class anti-inflammatory and anti-oxidant that activates Nrf2, a pathway involved in the progression of CKD. A Phase 2b study was completed in a global Phase 3 trial was recently initiated. Abbott's agreement with Reata Pharmaceuticals includes international rights to bardoxolone, excluding certain Asian markets.

• Women's Health

• Elagolix, a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) is in development for the treatment of endometriosis-related pain and fibroids. A Phase 2 study in endometriosis was recently completed. Abbott is working in partnership with Neurocrine to finalize the Phase 3 study design in endometriosis and a Phase 2 study in uterine fibroids was recently initiated.

• Neuroscience / Pain

• Abbott is conducting innovative research in neuroscience, where it has developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions. Abbott has more than a dozen new molecular entities in clinical trials for conditions such as schizophrenia, pain, Alzheimer's disease, Parkinson's disease and multiple sclerosis (MS).
• Abbott's neuroscience pipeline includes a novel, next-generation antibody, daclizumab, which entered Phase 3 development in 2010 for MS. We announced, with partner Biogen Idec, positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis over one year. The study demonstrated significant reductions in annualized relapse rate and met key secondary endpoints.
• Abbott is pursuing compounds that could provide relief across a broad spectrum of pain states, such as chronic back pain, postoperative pain and cancer pain.

• Oncology

• Abbott's oncology pipeline includes therapies that represent promising, unique scientific approaches to treating cancer. Abbott is focused on the development of targeted treatments that inhibit tumor growth and improve response to common cancer therapies. Abbott currently has 11 new molecular entities in human trials for cancer.
• The oncology pipeline includes: Elotuzumab, an anti-CD37 antibody; ABT-869, a multi-targeted kinase inhibitor; ABT-263, a Bcl-2/Bcl-xl protein antagonist; ABT-199, a Bcl-2 selective antagonist; and ABT-888, a PARP-inhibitor. Each is being studied in a variety of cancers. Additionally, Abbott is evaluating a number of other promising mechanisms, including work on EGFR, CD37, aurora kinase and cMET, among others.
• Abbott also has several oncology collaborations, including elotuzumab, currently in Phase 3 development for multiple myeloma.

• Immunology

• Abbott's scientific experience with the anti-TNF biologic HUMIRA serves as a strong foundation for its continuing research in immunology. Abbott is developing a number of additional indications for HUMIRA and is working to advance its early discovery programs, including oral DMARD therapies, and other potential biologic targets. Earlier this year we submitted U.S. and European regulatory applications for HUMIRA as a treatment for UC.
• Our agreement with Biotest brings Abbott rights to develop and commercialize BT-061, a novel anti-CD4 biologic in Phase 2 development for rheumatoid arthritis and psoriasis.
• Additionally, Abbott's proprietary DVD-Ig technology represents an innovative approach that can target multiple disease-causing antigens with a single biologic agent. This technology could lead to combination biologics for complex conditions such as cancer or rheumatoid arthritis, where multiple pathways are involved in the disease. We expect this program to move into Phase 1 clinical trials by year end.

• Molecular Diagnostics
  • Abbott expects to launch more than 15 new molecular diagnostic products over the next few years, including several novel oncology and infectious disease assays. In 2011, Abbott received U.S. FDA approval and CE Mark for an ALK gene rearrangement test for non-small-cell lung cancer to be used in combination with Pfizer's XALKORI (crizotinib), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor. Abbott also recently received FDA clearance for the Vysis EGR1 FISH Probe Kit to aid in determining the prognosis of patients with acute myeloid leukemia and chronic lymphocytic leukemia. Additionally, Abbott received FDA approval for the Abbott RealTime PCR HCV assay for measuring viral load, or the amount of hepatitis C virus in a patient's blood, as well as CE Mark for a new test to detect cytomegalovirus (CMV), a virus that can lead to complications in transplant patients and people who are immunocompromised.

• Diagnostics

• Abbott has launched a number of key assays on its ARCHITECT immunochemistry platform, which will significantly broaden its industry-leading menu. These tests include assays to assess ovarian cancer, vitamin deficiencies, and the first HIV combination assay approved for use in the United States. Future growth for the Core Laboratory Diagnostics business will be driven by differentiated analyzers and comprehensive automation and informatics solutions to provide high-quality results and information while enhancing laboratory productivity and reducing costs.

• Vascular Devices

• Abbott has one of the industry's most robust vascular pipelines and expects to deliver approximately 20 new coronary, endovascular and structural heart technologies over the next five years. Abbott is working on well-staged incremental advances, and truly game-changing technologies that have the ability to restate the market.
• ABSORB Bioresorbable Vascular Scaffold (BVS) – Abbott received CE Mark in Europe for the world's first drug-eluting BVS for the treatment of coronary artery disease. ABSORB restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves, leaving patients with a treated vessel free of a permanent metallic implant. Abbott has the most advanced BVS clinical program in the industry. Abbott recently initiated ABSORB BTK, an international clinical trial evaluating the safety of the ABSORB BVS for the treatment of below-the-knee (BTK) critical limb ischemia, a severe form of peripheral artery disease. Also, the company continues to expand clinical study of ABSORB to additional countries through the ABSORB EXTEND trial. Patients were recently treated with ABSORB for the first time in Japan, Hong Kong and Brazil.
• MitraClip – MitraClip® is a minimally invasive device for the treatment of select patients with mitral regurgitation (MR), the most common valve disease in the world. Significant MR affects more than 8 million people in the United States and Europe, and is four times more prevalent than aortic stenosis. Abbott's MitraClip system is on the market in Europe and a number of other countries and is currently under U.S. FDA review.
• Next-generation DES – Abbott has several next-generation DES platforms in development. Our XIENCE nano DES for small vessels launched in the United States in 2011. XIENCE PRIME, our next-generation drug-eluting stent (DES), offers improved deliverability, especially in long lesions. XIENCE PRIME is on the market in Europe with an expected U.S. launch in early 2012. Our ultra-thin DES is also in development. It's designed to improve clinical outcomes by reducing vessel injury upon deployment, enabling faster healing and improved deliverability in complex anatomy.
• Core Coronary products – Abbott is continuing to expand its position in the more-than- $2 billion core coronary market. Abbott launched its next-generation balloon dilatation catheter, TREK®, in Europe last year and in the United States and Japan in early 2011, and plans to introduce additional balloon catheter products and next-generation guide wires within the next few years.
• Endovascular products – Abbott's endovascular business continues to grow, led by recent launches of key products, including the Armada 14 balloon line, the expanded indication for the RX ACCULINK® Carotid Stent System and R&D investments into growth segments of the market for peripheral artery disease and vessel closure. In the United States, we recently launched the RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis in patients with uncontrolled hypertension.

• Vision Care

• Abbott expects numerous new products and technology advancements over the next five years, including the launch of a new contact lens solution that is underway in Europe and the United States. In its market-leading LASIK business, Abbott is expanding its proprietary laser platform into new vision correction applications, including cataract surgery. Abbott also continues to expand its premium and standard intraocular lenses (IOL), including Synchrony®, its next-generation IOL approved in Europe and other countries around the world. Synchrony is currently under FDA review in the United States.

• Nutrition
  • Abbott is focused on improving six areas through nutrition: immunity, cognition, lean body mass, inflammation, metabolism and tolerance. We expect to launch a number of new products and formulations to consumers in 2011 and are currently conducting 30 well-controlled clinical trials to demonstrate proven clinical outcomes with our nutrition innovation. Abbott has introduced several new products, including Ensure® with Revigor™, PediaSure SideKicks™, ZonePerfect® Sweet & Salty nutrition bars and Glucerna® Hunger Smart™ shakes and bars.